Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Table 2 Results of the final models of logistic regression analysis for predictors of clinical remission at weeks 8 and 56, biological remission at week 16 and loss of response to ustekinumab

Outcome	Variable	p value	Odds ratio	Confidence interval 95%
Clinical remission at week 8	Age	0.004	0.969	0.949–0.990
	Proximal disease (L4)	0.024	1.997	1.095–3.644
	Perianal disease	0.006	0.437	0.241–0.792
	Combotherapy^a	0.02	0.440	0.220–0.872
Clinical remission at week 56	Age < 17 years (A1)	0.015	5.667	1.395–23.017
Clinical remission at week 56	Smoking	0.002	0.110	0.028–0.434
Biological remission at week 16	Steroid dependence	0.009	0.356	0.164–0.769
Biological remission at week 16	B2/B3 behavior	0.003	0.316	0.147–0.681
Loss of response	Increased biomarkers^b	0.01	2.812	1.276–6201

Only variables in the univariate analysis with a p value < 0.20 were considered for the logistic regression model
^aCombotherapy refers to the concomitant use of ustekinumab with an immunosuppressor (thiopurines or methotrexate)
^bIncreased C-reactive protein (> 5 mg/L) and/or fecal calprotectin (> 250 µg/g) at baseline